Abstract
4004Background: Patients with advanced pancreatic neuroendocrine tumors (pNETs) have few treatment options that yield objective tumor regression. Somatostatin analogues, everolimus, and sunitinib y...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
